Format

Send to

Choose Destination
Drug Discov Today. 2010 May;15(9-10):332-41. doi: 10.1016/j.drudis.2010.02.003. Epub 2010 Feb 17.

Angiotensin-converting enzymes and drug discovery in cardiovascular diseases.

Author information

1
Department of Human Sport Science, Beijing Sport University, Beijing 100084, China.

Abstract

Angiotensin-converting enzyme (ACE) is a major target in the treatment of cardiovascular diseases (CVDs). In addition to ACE, ACE2 - which is a homolog of ACE and promotes the degradation of angiotensin II (Ang II) to Ang (1-7) - has been recognized recently as a potential therapeutic target in the management of CVDs. This article reviews different metabolic pathways of ACE and ACE2 (Ang I-Ang II-AT1 receptors and Ang I-Ang (1-7)-Mas receptors) in the regulation of cardiovascular function and their potential in new drug development in the therapy of CVDs. In addition, recent progress in the study of angiotensin and ACE in fetal origins of CVD, which might present an interesting field in perinatal medicine and preventive medicine, is briefly summarized.

PMID:
20170743
PMCID:
PMC3005694
DOI:
10.1016/j.drudis.2010.02.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center